We have previously reported the production of monoclonal antibodies (MAb) recognizing the core protein of a basement membrane-specific chondroitin sulfate proteoglycan (BM-CSPG). Using immunohistochemical techniques, we have shown that BM-CSPG is present in almost every basement membrane, one exception being the normal glomerular capillary basement membrane (GBM), where it is absent.
Introduction
The pathophysiology associated with the progressive nephropathy in some patients afflicted with long-term diabetes mellitus has been well described in the literature (1) (2) (3) (4) (5) . To assign a structurelfunction relationship to diabetic glomerulosclerosis, morphologists described mious histoarchitectural changes in sclerotic glomeruli, the most prominent of which include thickening of the glomerular capillary basement membrane (GBM) and expansion of the mesangial matrix (6,7) . Subsequent ultrastructural studies employed stereology to directly quantify the degree of change in the glomeruli of afflicted individuals (1.8-ll) , and indirectly demonstrated that overproduction of both glomerular extracellular matrices occurs in nephropathy. Biochemical and immunohistochemical investigations have extended those morphometry studies and now have directed present research endeavors towards determining factors in the di: betic condition that affect basement membrane component biosynthesis (12) (13) (14) (15) .
Basement membranes are complex extracellular matrices, in essence a structural composite consisting of glycoproteins (e.g.. laminin, fibronectin, entactinlnidogen), fibrillar proteins (Type IV collagens), and proteoglycans (PGs) (for review see [16] [17] [18] [19] [20] . Originally basement membranes were thought to be homogeneous in composition and to serve a single function, that of providing support for the cellular constituents of tissues. However, it is now understood that the composition of these matrices is highly tissue specific (21) . The uniqueness of each basement membrane, in turn, is thought to contribute in part to increasing numbers of tissuespecific functions that have been assigned to those particular structures.
In contrast to basement membrane glycoproteins and collagens, understanding of the cell and molecular biology of the basement membrane PGs is still in its early stages. Several PGs are known to exist in basement membranes, categorized by the glycosaminoglycan (GAG) chains they bear. Heparan sulfate proteoglycans (BM-HSPGs) were the first described BM PGs and at present are the best understood, since both the GAG chain composition (glucosaminoglycans) and the amino acid sequence deduced by cDNA McCARTHY, ABRAHAM", BYNUM, ST. JOHN, COUCHMAN cloning of the core protein for perlecan, the prototype member of the BM-HSPG family, have now been reported by several groups (22-24). In addition, several other smaller HSPGs have been reported in basement membranes (25,26). Whether they are distinct entities within the BM is an area of current investigation, as there is evidence suggesting that the core proteins of some of these smaller HSPGs arise as a result of post-translational processing of perlecan (27). However, there are also immunochemical and amino acid sequence data suggesting otherwise, i.e., that some of the smaller BM-HSPGs are unique molecules with distinct core proteins (25,26,28) .
In addition to BM-HSPGs, there are PGs whose core proteins appear to be different from perlecan and bear chondroitiddermatan sulfate chains (galactosaminoglyca) . At present two proteoglycans have been identified: PG-1000, a PG from the electric organ of marine rays (29,30) and BM-CSPG (31). The characterization, tissue distribution, and ultrastructural localization of BM-CSPG in adult and developing mammalian tissues have been described previously (31-37). Although the amino acid sequence for the core protein of BM-CSPG is unknown, immunochemical studies have indicated that the BM-CSPG core protein is different from that of perlecan (31).
The normal adult renal glomerulus, when viewed with regard to BM PG distribution, demonstrates the tissue specificity of basement membranes, shown by both biochemical and immunohistochemical techniques (31,34,35). Members of the BM-HSPG family are the dominant PG species in the GBM, where they have been proposed to play an active role in GBM filtration function (38). The mesangial matrix, on the other hand, appears to be composed of a mixture of BM-HSPGs and BM-CSPG. These different distribution patterns of PG populations appear to arise during the latter phases of glomerular maturation in mammals (35). In addition to BM PGs, both mesangial and glomerular epithelial cells are capable of synthesizing other galactosaminoglycan-bearing PGS in vitro, such as biglycan and decorin, usually resident in the interstitid extracellular matrix (12J3).
Glomerular PG biosynthesis is also altered in diabetes mellitus, the "lesion" presently believed to be a net decrease in the anionic site density of the GBM (39-43), perhaps as a result of a net decrease in sulfation of the GAG chains (44, 45) . It has been suggested that this defect in turn may contribute to the progressive loss of renal filtration function in diabetic glomerulosclerosis, either directly by altering the permeaselectivity function of GBM BM-HSPG or indirectly by the loss of BM-HSPG from the GBM by a decrease in charge-charge interaction with other basement membrane components in the GBM (46, 47) . In this report we show that the normal distribution of BM-CSPG is also altered in the diabetic condition. We show that BM-CSPG becomes abnormally associated with the GBM of diabetic rats and that its association with that structure appears to affect the structural/functional dynamics of the GBM membrane in a way that might directly contribute to its eventual dysfunction.
Materials and Methods

Materials
The characterization of monoclonal antibody (MAb) 2D6 recognizing the core protein of a basement membrane-specific chondroitin sulfate proteoglycan (BM-CSPG) (31) and polydonal antibodies that recognize the core protein of a basement membrane heparan sulfate proteoglycan (BM-HSPG) (26) and laminin (48) have been reported previously. Non-immune mouse IgG was obtained commercially (Jackson Immunoresearch; West Grove, PA), as were fluorescein (FIX)-conjugated goat anti-mouse IgG (no crossreactivity to rat) and rhodamine (TR1TC)-conjugated goat anti-rabbit IgG secondary antibodies (Organon Teknika-Cappel; Durham, NC). All chemicals, unless otherwise stated, were obtained from Sigma (St Louis, MO).
Animals and Animal Care
F6ty age-matched male Sprague-Dawley rats (Charles River; Kingston, NY) were divided into two groups. Baseline serum glucose levels (49) and body weights were obtained for all animals before the beginning of the study. One group (30 animals) received a single IP injection of streptozocin (65 mglkg b.w.) dissolved in normal saline buffered with 20 mM sodium citrate. pH 4.5 (CBS); the second group (20 animals) received IP injections of CBS. Non-fasting serum glucose levels and body weights were obtained for all animals 1, 4, 8, and 24 weeks after injections. Animals in the diabetic group with non-fasting serum glucose levels <300 mg/dl were not included in the study.
Tissue Processing
Light Microscopy. Animals from both groups were killed 4, 8, 12, or 24 weeks after injection and the tissues either fixed in acid alcohol (50) for paraffin embedding or snap-frozen in 2-methylbutane-acetone-solid CO2 as described previously (31,34). To avoid bias in preliminary studies, sections from both normal and diabetic animal groups were coded by an impartial observer, immunostained, examined, and differential identification (control vs diabetic) made, based on the known staining pattern of BM-CSPG in the normal kidney (31.34). In subsequent studies, which examined the relative change of BM-HSPG and BM-CSPG within the same glomerulus, a double-label immunofluorescence protocol (31.34) was used. Brietly, acid-alcohol fixed tissues were dehydrated through a series of graded alcohols (80-95-100%). cleared in xylene, and embedded in paraffin (Tissue-Prep; Fisher Scientific, Pittsburgh, PA). Afterwards, sections were cut at 4 pm with a rotary microtome (Reichert; Buffalo, NY) and affixed to glass slides. For immunostaining of paraffin sections, slides were cleared in two changes of xylene and rehydrated through a graded alcohol series (100-95-80-70-50% ethanol for 2 min). The sections were then digested for 15 min in a solution of bovine testicular hyaluronidase in PBS (15.000 U/ml) (51). Afterwards, the sections were rinsed three times for 10 min in PBS. From this point on the immunostaining procedure was the same as described for frozen sections (26). Primary antibody localization for BM-CSPG MAb was detected with FIX-conjugated goat anti-mouse IgG (no crossreactivity to rat IgG) (OrganonlTeknica; Durham, NC) as a secondary antibody (1:50 dilution). For primary antibody localization of anti-HSPG antiserum (26), WE-conjugated goat anti-rabbit IgG (OrganonlTeknica) was used. In all circumstances, the MAb were applied first in the doublelabel protocol.
For single-label studies, negative controls included omission of the primary antibodies or non-immune mouse IgG in place of the MAb. In the case of the polyclonal antiserum, the pre-immune serum from the rabbit used to raise the anti-HSPG serum was used. These controls gave nonspecific background fluorescence in each case. Controls for the double-label studies included tissue sections stained with (a) single primary antibodies followed by inappropriate secondary antibodies, (b) one primary antibody with both secondary antibodies, and (c) secondary antibodies alone. Control b was positive only for the appropriate secondary antibody. Controls a and c were negative. Some tissue sections were also counterstained with Hoechst 33257 stain to show the location of cell nuclei within a given glomerulus.
All h u e sections were viewed on a Nikon Optiphot microscope equipped with epifluorcscent illumination optics and appropriate filters. Photomicrographs were taken on Ilford HP-5 or Kodak Ektachrome-400 film.
The altered pattern of BM-CSPG immunostaining was used to quantlfy the time course of the early stages of sclerotic change in glomeruli from animals (three animals/group) of 1,2, and 3 months' duration of untreated diabetes mellitus. Tissues from the appropriate age-matched normal animals (three animalslgroup) were used as controls. Tissue sections ofwhole kidneys cut in sagittal section were immunostained using the MAb against BM-CSPG as described in the above single-label protocol. For counting purposes, tissue sections were examined with a x 20 objective lens, the field of view scanned from the outer cortex inwards to the juxtamedullary region and back during the counting. Fifty glomeruli/animal were counted and were categorized as either normal, early, intermediate, or late stage of sclerosis on the basis of morphologies depicted in Figure 1 Elecaon M i c " p y . For immunoelmron microscopy studies, MAb 2D6 IgGl was affinity-purified from mouse ascites fluid with protein G (Pharmacia; Piscataway, NJ) according to published methods (52) . AntiWy purity was subsequently verified by SDS-PAGE. Horseradish peroxidase (HRF') was covalently coupled to 2D6 MAb IgG1, non-immune mouse IgG (Jackson Immunoresearch), or sheep anti-laminin antiserum (48) according to the method of Nakane and Kawoi (53) . The resultant conjugate was dialyzed into PBS and concentrated to 1-2 mg/ml before injection into animals for E M studies.
Animals with 2 and 6 months' duration of diabetes mellitus and agedmatched control animals were anesthetized with ether; 2 mg of antibody-HRP conjugate in PBS was injected via the femoral vein and they were allowed to recover. After 4 hr the animals were euthanized by ether overdose, the abdominal cavity opened, and the kidneys infiltrated with a hypodermic needle and fixed in situ with Karnovsky's fixative (54) . The kidneys were excised, the cortex separated from the medulla, and cortical pieces were fixed for 2 hr in the same fmative. The tissue was rinsed for three 10-min changes with Sorensen's phosphate buffer, pH 7.4, with 3.5% sucrose, then processed for peroxidase cytochemistry (55). The tissues were dehydrated through a graded series of alcohols (30-50-70-80-95-100%) and propylene oxide, and embedded in EMBED-812 (Polysciences; Warrington, PA) according to the manufacturer's directions. Tissue sections were cut at 80 nm with a Nova Ultramicrotome (Cambridge Insuuments; Buffalo, NY) equipped with a diamond knife (Diatome USA; Ft Washington, PA), collected on 200-mesh copper grids, and subsequently counterstained with lead citrate (56). The tissue sections were examined and photographed with a Hitachi H-7000 transmission electron microscope.
Results
Before injection, all animals had non-fasting blood glucose levels of 120-180 mg/dl. One week post injection, the majority (26130) of the animals receiving streptozocin had non-fasting blood glucose levels of >400 mgldl. Blood glucose levels for control animals were normal. Urinary output volumes were measured in animals remaining in the study at 2 months; average 24-hr urinary output for controls was 11 ml compared with 100 ml for diabetic animals.
During the course of the study the body weights of diabetic animals markedly decreased compared with those of the control animals. Figure 1 shows the immunostaining patterns characteristic for BM-CSPG (A) and BM-HSPG (B) (31, 34) . In normal animals, BM-CSPG is localized in the basement membrane of Bowman's capsule and mesangial matrix but is not found in the pericapillary GBM (31,34). Because of this specific pattern of immunolocalization, BM-CSPG immunostaining can be used as a marker for total mesangial matrix within a normal adult glomerulus. In contrast, BM-HSPG immunostaining ( Figure 1B) is associated with all three of the above structures; the GBM in this panel is indicated by arrowheads. Figure IC, an in-camera triple exposure of A and B, illustrates further that BM-CSPG is absent in the BM (arrowheads) of normal animals. In this case the yellow coloration in the micrograph is indicative of exact co-distribution of both PG populations, and therefore this technique can be used to show the specific compartmentalization of two PG populations within the glomerulus (31J4). EM studies ( Figure 2 ) of glomeruli from normal animals injected with MAb 2D6-HRP conjugate corroborated the LM observations showing that BM-CSPG is limited to the mesangial matrix of the normal adult glomerulus. The ultrastructural studies revealed that BM-CSPG maintains its segregation from the GBM in the mesangial region, consistently being found directly subjacent to the lamina densa of the perimesangial portion of the GBM and the juxtamesangial portions of capillary endothelial cells. This relationship was consistently maintained in the glomeruli of diabetic animals ( Figure  3A ). BM-CSPG was evenly distributed within the mesangial matrix proper and was found within "bays" formed by the cytoplasmic processes of mesangial cells. In normal animals the close association of BM-CSPG with the GBM terminates in the area of the mesangial "neck," where the GBM becomes part of the glomerular capillary wall. Consistent with its abrupt boundary at the mesangial neck, the pericapillary GBM was negative for BM-CSPGassociated immunoreactivity, as previously shown (3537). The mesangial matrix and the GBM of control animals injected with a non-immune mouse IgG-HRP conjugate were completely negative for HRP-associated immunoreactivity (data not shown).
BM-CSPG and BM-HSPG Distribution in Normal Glomeruli
Glomerular BM-CSPG Localization Is Altered in Diabetic Animals
Changes from the normal pattern of glomerular BM-CSPG distribution were readily detectable in glomeruli from diabetic animals as early as 1 month after injection with sueptozocin (not shown). Although the majority of glomeruli showed a pattern of glomerular BM-CSPGIBM-HSPG immunostaining similar to that observed in normal glomeruli (Figures IA-lC), some glomeruli exhibited morphology similar to Figure 1D -IF (2-month diabetic glomerulus).
Glomeruli from kidneys from diabetic animals of 2 months' duration showed more variability in the patterns of BM-CSPG staining. Normal glomeruli, with patterns of BM-CSPG distribution similar to that seen in Figures 1A-1C (age-matched control), were found in all tissue sections. However, the BM-CSPG distribution pattern of some of the glomeruli resembled that shown in Figure  ID . The glomeruli appeared slightly hypertrophic ( Figure 1A ; cf. Figure ID) , with an apparent increase in the intensity and extent of BM-CSPG staining within the mesangial matrix. In these glomeruli BM-CSPG was also found within the GBM ( Figure ID distribution was unlike that seen in control animals, where BM-CSPG was absent from the GBM. Electron micrographs (Figure 3) of glomeruli from 2-month diabetic animals immunostained in vivo with MAb 2D6-HRP conjugate further corroborated the LM observations. At the ultrastructural level, BM-CSPG was found in the mesangial matrix of diabetic animals in a pattern similar to that seen in normal animals (cf. Figure 2) . although the density of peroxidase-associated reaction product appeared greater in the diabetic glomeruli. However, BM-CSPG was also associated with the pericapillary GBM ( Figure 3A) , immediately subtending the capillary endothelial cells. The pattern of BM-CSPG deposition within the majority of capillaries in affected glomeruli differed from the continuous rim of BM-CSPG-associated staining seen in the immunofluorescence light micrographs (Figure ID) . Instead, BM-CSPG had a focal pattern of deposition ( Figure 3A and inset) in those affected capillaries. In some sections, BM-CSPG deposition was coincident with areas where the basement membrane was ostensibly thickened (double arrows). The accumulation of BM-CSPG- positive material in these areas appeared to displace the capillary endothelial cells from the basement membrane proper (Figure 3A , boxed area, inset). In some areas (Figure 3A, double arrows) , loss of endothelial cell fenestration was observed. Effacement of podocyte (P) foot processes (fp) was coincident with the endothelial changes seen in this area, strongly suggesting that altered cell-cell interactions may be occurring in these regions. Interestingly, in other areas of these same affected capillaries, BM-CSPG was absent and the basement membrane was of apparently normal thickness (Fig  ure 3, thick arrow) . Parallel in vivo labeling studies showed that the pattern of immunoperoxidase label distribution is unique to BM-CSPG, since anti-laminin-HRP conjugates injected into other diabetic animals labeled the entire thickness of GBM (Figure 4) .
Likewise, when normal or diabetic animals were injected with the non-immune mouse IgG-HRP conjugate, both the mesangial matrix and GBM were completely negative for HRP-associated immunoreactivity, demonstrating that passive trapping of antibody-HRP conjugate does not occur in the diabetic GBM (data not shown).
In some tissue sections ofkidneys from 2-month diabetic animals, a minority of glomeruli with morphologies similar to that shown in Figures 1G-11 and 1J-lL was also seen. In these glomeruli, the morphologies of which suggest more advanced stages of glomerulosclerosis, the pattern of PG distribution was different from that seen in previous specimens. In these glomeruli, BM-CSPG-positive material ( Figures 1G and 4 . arrows) was found within capillary lu- cates the portion of the capillary wall that is enlarged in the inset. (A) Several glomerular capillaries as well as the mesangial matrix (M) contain electron-dense HRP reaction product indicating BM-CSPG immunolocalization. In affected capillaries, EM-CSPG immunoreactivity is found between the capillary endothelial cell and the pericapillary GBM (double arrows, boxed area). The pericapillary GBM is ostensibly thickened in these same areas. Within the same field at lower left corner is a capillary loop whose pericapillary GBM is of apparently normal thickness and lacking in BM-CSPG immunoreactivity (thick arrow). mens, the staining being internal to that of BM-HSPG ( Figures  1H and lK, arrows) . In some sections where the capillaries were cut along the longitudinal axis, BM-CSPG immunostaining was clearly present within capillary lumens ( Figures 1G and 11, arrows) . In a severely sclerosed glomerulus ( Figures 1J and 1L) , BM-CSPGpositive material almost occluded the glomerular capillary lumen.
In glomeruli with this morphology, BM-HSPG (Figure lK, arrows) staining was ostensibly decreased, being localized as a thin rim of immunofluorescence around the periphery of the areas positive for BM-CSPG (Figure lJ) . The in-camera double exposure (Figure 1L) showed that the majority of the staining in the existing glomerular tuft is BM-CSPG, with relatively little BM-HSPG within the glomerular tuft. EM of glomeruli from animals with 6 months' duration of untreated diabetes ( Figure 3B ) showed glomeruli with capillaries having a pattern of BM-CSPG-associated immunoreactivity similar to that seen at 2 months associated with the GBM, i.e., a subendothelial pattern of distribution. However, the extent of BM-CSPG-labeled material within affected capillary loops appeared to have increased, the composition of the majority of the filtration surface altered with the presence of BM-CSPG. In addition to the subendothelial pattern of deposition ( Figure 3B, arrow) , BM-CSPG immunoreactivity was also found in the pericapillary GBM proper.
We used the altered pattern of BM-CSPG immunostaining in diabetic glomeruli to monitor the progression of sclerosis in animals of 1,2, and 3 months' duration of untreated diabetes mellitus. Figure 5 depicts the transition from normal (cf. Figure 1A Figure 1G ). We were unable to detect any glomeruli in the late-stage category (cf. Figure 1J) in any of the sections used in our counting protocol, suggesting that these particular glomeruli constitute a minority of the total glomerular pool in the early stages of the disease. At 1 months' duration of untreated diabetes, glomeruli in the normal category made up the majority (70%) of the glomeruli counted, with the remainder of the glomeruli having morphology of early sclerotic change. At 2 months' duration of disease, there was an alteration in the ratio of normal/early-stage change, with approximately 52% of the glomeruli counted now showing altered morphology. At this time a minority ofthe glomeruli (2%) showed changes in the intermediate category. Glomeruli from animals in the 3-month duration group showed even more dramatic changes, with only 20% of the glomeruli exhibiting normal morphology and 56% of the glomeruli showing changes in the early category. However, glomeruli with morphology in the intermediate-change category now comprised 22% of the glomeruli counted.
Discussion
We have previously shown through the use of immunohistochemical methods that there is spatial segregation of glomerular PG populations in normal adult animals. BM-HSPGs are found in the GBM and mesangial matrix, whereas BM-CSPG is resident exclusively in the mesangial matrix (31, 34) . These findings support the results of earlier biochemical analyses of the composition of the GBM and mesangial matrix. The results of the present study show that this characteristic pattern of distribution of BM-CSPG is altered in disease, i.e., that BM-CSPG is abnormally associated with the pericapillary GBM of streptozocin-induced diabetic rats. To the best of our knowledge, this is the first report of a BM component being abnormally associated with the GBM as a result of diabetes mellitus.
When the pattern of BM-CSPG immunostaining was used as a marker to detect the initiation of sclerotic events in diabetic glomeruli, we were able to discern the transition from normal to mild change as early as 1 month after induction of diabetes ( Figure  5) , with an increase in the number of glomeruli entering the sclerotic process with increasing duration of untreated disease. These findings indicate that the process is progressive rather than an "all-ornothing" manner and, in part, supports similar observations in human by Hgrlyck et al. (58) . Our study also showed that within the affected glomeruli the process is both segmental and focal, i.e., not all capillary loops within an affected glomerulus are positive for BM-CSPG and, in the early stages of disease progression, not all parts of affected capillaries are immunoreactive for BM-CSPG. Rather, it appears in focal regions of the capillary basement membrane. The above observations suggest that biochemical analyses of extracellular matrix molecules based on "pooling" of glomeruli obtained by sieving kidneys of diabetic animals may not accurately reflect actual local changes in the amount of extracellular matrix in diabetic glomeruli progressing towards sclerosis, since pooled material would potentially contain a mixture of both normal and diabetic glomeruli. This situation can be also extended from the protein level to the mRNA level, i.e., the interpretation of message levels for extracellular matrix proteins from pooled preparations could be shaded in a similar manner. Therefore, to accurately discern initiation of early sclerotic events for future studies, it may be necessary to employ markers such as altered distribution of BM-CSPG to identify glomeruli progressing towards sclerosis.
Results of the present IEM study showed that abnormal BM-CSPG deposition is associated with focal areas of pericapillary GBM thickening. Although it is appealing to infer that the presence of BM-CSPG in these areas might directly alter the local biodynamics of pericapillary GBM turnover or its filtration function, there was no direct experimental evidence in this study to support this premise.
Several studies that used antibodies directed against heparan sulfate GAG chains (59) or heparan sulfate PG core protein (60) offer evidence that interference with normal GBM turnover (60) can lead to alterations in both structure and function ofthe GBM. Although both studies reported the induction of albuminuria as a result of in vivo injection of antibodies, the study by Miettinen et al. (60) also noted thickening of the GBM over time, leading to the proposal that antibody binding directly affected the turnover of the GBM. The effects described in both studies, however, were due to direct antibody-ligand interaction. The pattern of abnormal BM-CSPG deposition places it on the subendothelial side of the pericapillary GBM proper, thereby relegating it to a position capable of direct interaction with capillary BM-HSPG-perlecan. However, it is unknown at this time if BM-CSPG and BM-HSPG-perlecan do interact and whether the result of such interaction could affect the turnover/function of the BM-HSPG population. An alternative proposition to the above mechanism for GBM thickening is that the effect may be mediated indirectly, i.e., in areas of focal BM-CSPG accumulation the normal cell-cell interactions between the glomerular epithelial and endothelial cells are altered in such a way that may promote matrix accumulation in that site.
When the results of the present study are related to those of an earlier report of the pattern of expression of BM-CSPG in glomerular development (35), they strongly suggest that the process could be an abnormal reiteration of events that occur during normal glomerular development. During the latter stages of glomerular maturation, BM-CSPG is transiently associated with the pericapillary GBM as part of the normal developmental sequence (35) . Direct comparison of the pattern of pericapillary GBM BM-CSPG distribution in immunofluorescence micrographs of diabetic glomeruli and glomeruli in the latter stages of maturation shows similar morphologies, although in the maturing glomerulus the mesangial matrix has a normal rather than a hypertrophic appearance. On first examination, the ultrastructural pattern of deposition suggests that the capillary endothelial cells could be responsible for the production of BM-CSPG in both events (see below). However, the BM-CSPG distribution pattern in the maturing glomerulus is subtly different from the results reported here for the early stages of the disease. Unlike the exaggerated subendothelial layer of deposition seen in diabetic glomeruli, the micrographs of the maturing capillary loops show BM-CSPG more discretely localized within the pericapillary GBM. As mentioned in the previous report (35), the initial presence and the subsequent loss of BM-CSPG in the developing GBM might be an indication of GBM maturation, signaling the transition of the GBM to an active filtration surface. Our results suggested that the removal of BM-CSPG during GBM maturation occurs partially by attrition, i.e., that the podocytes, the cell population responsible for production of mature GBM, do not make basement membrane material that contains BM-CSPG. Therefore, an additional and perhaps important consequence of the diabetic condition exists: the accumulation of BM-CSPG in the GBM occurs in part because the adult glomerulus lacks a mechanism for routine removal of BM-CSPG from the pericapillary GBM once it becomes associated with the GBM.
The specific mechanism by which BM-CSPG is deposited into the GBM is unknown but is currently an area of active investigation. The pattern of deposition onto the GBM suggests several possibilities. As mentioned above, the association of BM-CSPG with the affected glomerular capillaries in diabetic animals suggests that either the podocytes or endothelial cells, known to participate in early glomerular capillary wall formation (61) . are stimulated by conditions present in diabetes to initiate BM-CSPG production. However, when the microanatomy of the glomerulus is taken into consideration (62), one must accept that a third alternative is possible: BM-CSPG could be overproduced by mesangial cells and physically translocated into the GBM from the mesangial matrix (1) or, along a similar vein, BM-CSPG (or its fragments) is "sloughed off' from the expanding mesangial matrix to become passively trapped in the subendothelial space of the lamina rara interna of the GBM.
In the latter part of glomerular development and maturation, the visceral epithelial cells (podocytes) are considered the primary biosynthetic source of GBM components (48, (63) (64) (65) . Recently, it has been shown that isolated glomerular epithelial cells can synthesize chondroitiddermatan sulfate PGs, such as decorin, in vitro (13, 66) . However, the primary GBM PGs synthesized by intact glomeruli are members of a family of heparan sulfate PGs (27, 67) . Although the mechanism by which podocytes insert newly synthesized basement membrane into existing GBM (i.e., splicing) (48) readily provides an explanation for the focal pattern of BM-CSPG deposition seen in the early stages of sclerosis at the ultrastructural level, ifpodocytes were the source of BM-CSPG, then one would expect to find immunolocalization throughout the entire thickness of the GBM in a manner similar to that shown in Figure 4 for laminin. However, our results show that BM-CSPG has a consistent unilateral pattern of deposition, associated primarily with the subendothelial side of the GBM in diabetic animals ( Figure  3) . Our prior developmental studies also serve to further direct our attention from the podocyte. Although BM-CSPG was transiently present in the pericapillary GBM of maturing glomeruli, germane to this discussion is the fact that BM-CSPG was absent in newly synthesized basement membrane material destined for eventual "splicing" into the maturing GBM (35). Both results lead us to preliminarily exclude this glomerular cell population from consideration as the source of abnormal BM-CSPG production in diabetic glomeruli.
The immunolocalization of BM-CSPG to the subendothelial side of affected glomerular capillaries in diabetic animals could also be construed as indicating that capillary endothelial cells, which participate in the formation of the GBM in the early stages of nephrogenesis (61) . are abnormally stimulated to synthesize BM-CSPG in diabetics. We have previously shown that the microvasculature of other tissues, such as cardiac and skeletal muscle, is immunoreactive for BM-CSPG (31,34), suggesting that capillary endothelial cells in those tissues can synthesize the PG. Since BM-CSPG is normally absent from the glomerular microvasculature, one would surmise that if glomerular capillary endothelial cells are responsible for the abnormal deposition of BM-CSPG, then conditions, either local or systemic, must exist in the diabetic glomerulus that remove a constraint to BM-CSPG biosynthesis. One such factor, TGFP, which has been implicated in the up-regulation of extracellular matrix biosynthesis in glomerulosclerosis (12, 68) , is present in increased amounts in diabetic glomeruli (14). TGF-P has profound effects on chondroitin sulfate PG biosynthesis, increasing not only the amount of the PG produced but also the length of the GAG chains present on the molecule (69). Therefore, a stimulus for altered PG biosynthesis does exist within the diabetic glomerulus, and it is appealing to suggest that E F p plays, in part, a role in the mediation of such an event. Our results also show that the abnormal presence of BM-CSPG may directly affect cell behavior in the glomerular microvasculature of diabetics (i.e., disruption of the local capillary microenvironment within focal regions of affected glomeruli). Our electron micrographs show that the accumulation of BM-CSPG in the subendothelial side of the GBM causes the endothelial cell to be displaced from the GBM proper. In those regions where the endothelial cell cytoplasm is physically removed from direct contact with the GBM, the regular organization of the endothelial fenestrae is noticeably disrupted. Interestingly, in those same regions the pericapillary GBM is ostensibly thickened. However, whether or not the BM-CSPG is the cause or result of capillary architectural disruption is a hypothesis that remains to be tested.
The third alternative to the above hypotheses implicates the mesangial cell. In past LM studies we have shown BM-CSPG to be exclusively resident to the mesangial matrix in normal glomeruli of mature rats (31,34). Moreover, mesangial cells in culture have also been shown to make several species of chondroitin/dermatan sulfate PGs (12,70) including BM-CSPG (71, 72) . In a situation where the rate of biosynthesis outstrips degradation, it is possible that BM-CSPG is extruded from the expanding mesangial matrix into the capillary filtration surface via a "potential" space formed between the capillary endothelial cell and the peripheral capillary GBM. Observations from several other studies support this premise in part. It is well known that the biosynthetic dynamics of the mesangial matrix is profoundly affected by conditions present in diabetes mellitus. Stereology studies first demonstrated that, concomitant with the characteristic pericapillary GBM thickening in the diabetic glomerulus, an increase in the relative glomerular mesangial volume fraction, with an inherent increase in mesangial matrix, also occurs, the process known as mesangial expansion (10,ll). In the pathophysiology of end-stage renal disease, mesangial expansion is thought to compromise the filtration function of the glomerular capillaries by encroaching on the net space occupied by glomerular capillaries, thus decreasing the surface area available for capillary filtration (2). Moreover, as mentioned above, a stimulus that could in part be mediating mesangial expansion and increased CSPG production (i.e., EFD) is increased in the glomeruli of diabetics (14). Furthermore, recent ultrastructural morphology studies of glomeruli from diabetic animals have identified material present in the capillary lumen of glomeruli in the same location as reported here for BM-CSPG, i.e., intemal to the GBM proper and subjacent to the endothelial cells (73.74) . Both studies show that this material in the glomerular capillary is directly continuous with that of the mesangial matrix, implying that its origin is from the mesangial matrix. Immunohistochemical analysis of this material was not performed in either study, but, on the basis of our results, predictably should contain BM-CSPG.
